Tirzepatide: the dual-agonist GLP-1, explained
Tirzepatide is a dual GIP and GLP-1 receptor agonist and the most effective GLP-1-class weight-loss medication in head-to-head trials. Here is what it is, how it compares to semaglutide, and what it costs.
Tirzepatide activates two incretin receptors (GIP and GLP-1) rather than one, and in the SURMOUNT trials produced greater average weight loss than semaglutide. It is sold as brand Zepbound (weight management, sleep apnea) and Mounjaro (type 2 diabetes), and as compounded tirzepatide through telehealth programs at roughly $199–$297/month. Compounded tirzepatide is not FDA-approved.
How tirzepatide works
Tirzepatide is a single molecule that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Semaglutide activates only the GLP-1 receptor. The dual mechanism is associated with greater average weight loss in clinical trials, which is why tirzepatide is often described as the efficacy leader in the GLP-1 class, though individual response varies and side-effect profiles overlap.
Tirzepatide versus semaglutide
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide. Tirzepatide also costs more, both as brand and compounded, because its active ingredient is harder to source. For a patient choosing between them, the trade-off is efficacy and price: tirzepatide tends to deliver more weight loss at a higher cost, while semaglutide is cheaper with strong but generally lower average results. The decision belongs with a prescriber. See our tirzepatide cost guide and semaglutide cost guide.
Tirzepatide vs semaglutide at a glance
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Brand names | Zepbound, Mounjaro | Wegovy, Ozempic, Rybelsus |
| Avg weight loss (trials) | Higher (SURMOUNT-5 head-to-head) | Strong, generally lower |
| Compounded cost/mo | $199–297 (higher) | $145–178 (lower) |
| Brand list/mo | ~$1,086 (Zepbound) | ~$1,349 (Wegovy) |
Brand tirzepatide
Zepbound is approved for chronic weight management and, more recently, obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes. Both are the same molecule at the same dose ceilings; the brand and label differ by indication, which drives coverage. Compounded tirzepatide is a separate, non-FDA-approved category.
What it costs
Compounded tirzepatide runs roughly $199–$297 per month across legitimate providers; brand lists near $1,086 with LillyDirect self-pay vials from $299. Full breakdown, by provider and with evidence status, is in our tirzepatide cost guide.
Safety and eligibility
Common side effects mirror the GLP-1 class: nausea, diarrhea, vomiting, constipation. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Eligibility is determined by a licensed clinician after review of your history and medications. This is educational information, not medical advice.
Sources
- SURMOUNT-5 head-to-head (NEJM). nejm.org
- FDA — Zepbound and Mounjaro labels (Drugs@FDA). accessdata.fda.gov
- Pricing: our tirzepatide cost guide and evidence ledger.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $139 to $399 a month across the 12 programmes we can price, with a median of $298. The spread between cheapest and dearest is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $139 on its 12-month plan; Found follows at $169 (12-month prepaid). Half the market sits below $298 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
3 programmes additionally advertise a tirzepatide microdose, the cheapest at $147 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How tirzepatide is kept current
The tirzepatide figures on this page span $139 to $399 a month across 12 programmes. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose tirzepatide spans $139 to $399 a month across 12 programmes we can price, a spread of $260.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Why the spread is this wide
Standard-dose tirzepatide spans $139 to $399 a month across 12 programmes we can price, a spread of $260.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed tirzepatide cheaper?
Because it is less medicine. 3 programmes advertise a tirzepatide microdose, the cheapest at $147 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded tirzepatide?
NexLife at $139 a month at a standard therapeutic dose on the 12-month plan ($1,668 total), captured 2026-09-04. 6-month $149; 3-month $159; month-to-month $169. No membership fee, flat at every covered dose. Verified. The next-cheapest is Found at $169, which requires prepaying twelve months (Provider Reported).
What does compounded tirzepatide normally cost?
$139 to $399 a month across 12 programmes, with a median of $298. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.